Mutations in the U2 small nuclear RNA auxiliary factor 1 (U2AF1) gene are the common feature of a major subset in myelodysplastic syndromes (MDS). Creative Biolabs is a leading biotechnology company which has the extensive expertise in providing gene analysis service for customers. Advanced technologies and highly experienced staffs are available to provide you the complete U2AF1 analysis service with data visualization. Individual work packages made up of our modular structure can be tailored to your specific needs.
Scientific Validity
U2AF1 gene is an RNA shearing related gene, which is the early mutation gene of MDS. The mutation rate of U2AF1 gene in MDS patients is about 5% to 20%. U2AF1 mutation can affect the expression of p53 signaling pathway and MAPK signaling pathway proteins by down-regulating the transcription of related genes.
The mutation occurred more frequently in younger patients and was stable during disease evolution. Besides, U2AF1 mutation predicted poor prognosis, especially in lower-risk subgroup of patients as well as in younger patients. Therefore, U2AF1 mutation may be used as a biomarker for risk stratification and to monitor the response of treatment.
Fig.1 Structure of U2AF1.Distributed under CC BY-SA 3.0, from Wiki,
without modification.
Services at Creative Biolabs
Previous studies indicated that S34F mutant U2AF1 induces G2/M cell cycle arrest mediated by FOXO3a activation, which induces pyroptotic cell death. Creative Biolabs provides determination services to analysis the effects of FOXO3a on biological functions of S34F mutant U2AF1-expressing cells. Other featured services include but not limited to the following:
1. Next generation sequence
Creative Biolabs provides mutant gene detection services for U2AF1 analysis. PCR was used to amplify and sequence genes. Gene mutation detection was done with standard NGS technology on high-throughput sequencing platform.
2. U2AF1 construct generation and expression
Creative Biolabs provides wild-type or mutant U2AF1 cDNA generation services. A Kozak consensus sequence and desired tag is added to the N-terminus of U2AF1 isoforms. The resulting wild-type and mutant U2AF1 are then cloned into a lentiviral vector and used for transduction. Stable subclones are generated and validated by Sanger re-sequencing. Immunoblotting is used to confirm the expression level.
Interested in moving your program forward, but don't want to bring an assay in-house? Feel free to contact us for more information. Let's Discover Together.
For Research Use Only.
